text: COMUNICADO DE ROCHE Roche, OSI Pharmaceuticals and Genentech announced today that the US Food and Drug Administration (FDA) has approved, after priority review, Tarceva(TM) (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung 